Exact Sciences Corp
NASDAQ:EXAS
Exact Sciences Corp
Income from Continuing Operations
Exact Sciences Corp
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Exact Sciences Corp
NASDAQ:EXAS
|
Income from Continuing Operations
-$240.2m
|
CAGR 3-Years
31%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-17%
|
|
Abbvie Inc
NYSE:ABBV
|
Income from Continuing Operations
$4.9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Income from Continuing Operations
$456m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-21%
|
|
Amgen Inc
NASDAQ:AMGN
|
Income from Continuing Operations
$3.8B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Income from Continuing Operations
$3.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Income from Continuing Operations
$3.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
26%
|
See Also
What is Exact Sciences Corp's Income from Continuing Operations?
Income from Continuing Operations
-240.2m
USD
Based on the financial report for Mar 31, 2024, Exact Sciences Corp's Income from Continuing Operations amounts to -240.2m USD.
What is Exact Sciences Corp's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-17%
Over the last year, the Income from Continuing Operations growth was 54%. The average annual Income from Continuing Operations growth rates for Exact Sciences Corp have been 31% over the past three years , -2% over the past five years , and -17% over the past ten years .